127 related articles for article (PubMed ID: 17625456)
21. Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.
Nagore E; Montoro A; García-Casado Z; Botella-Estrada R; Insa A; Lluch A; López-Guerrero JA; Guillén C
Melanoma Res; 2009 Aug; 19(4):211-4. PubMed ID: 19571771
[TBL] [Abstract][Full Text] [Related]
22. Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients.
Council ML; Gardner JM; Helms C; Liu Y; Cornelius LA; Bowcock AM
Exp Dermatol; 2009 May; 18(5):485-7. PubMed ID: 19320745
[TBL] [Abstract][Full Text] [Related]
23. Phenotypic variation in familial melanoma: consequences for predictive DNA testing.
Bergman W; Gruis NA
Arch Dermatol; 2007 Apr; 143(4):525-6. PubMed ID: 17438187
[No Abstract] [Full Text] [Related]
24. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.
Goldstein AM; Liu L; Shennan MG; Hogg D; Tucker MA; Struewing JP
Br J Cancer; 2001 Aug; 85(4):527-30. PubMed ID: 11506491
[TBL] [Abstract][Full Text] [Related]
25. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
Bruno W; Pastorino L; Ghiorzo P; Andreotti V; Martinuzzi C; Menin C; Elefanti L; Stagni C; Vecchiato A; Rodolfo M; Maurichi A; Manoukian S; De Giorgi V; Savarese I; Gensini F; Borgognoni L; Testori A; Spadola G; Mandalà M; Imberti G; Savoia P; Astrua C; Ronco AM; Farnetti A; Tibiletti MG; Lombardo M; Palmieri G; Ayala F; Ascierto P; Ghigliotti G; Muggianu M; Spagnolo F; Picasso V; Tanda ET; Queirolo P; Bianchi-Scarrà G
J Am Acad Dermatol; 2016 Feb; 74(2):325-32. PubMed ID: 26775776
[TBL] [Abstract][Full Text] [Related]
26. Contribution of susceptibility gene variants to melanoma risk in families from the Veneto region of Italy.
Menin C; Vecchiato A; Scaini MC; Elefanti L; Funari G; De Salvo GL; Quaggio M; Tognazzo S; Agata S; Dalla Santa S; Montagna M; Alaibac M; Chiarion-Sileni V; D'Andrea E
Pigment Cell Melanoma Res; 2011 Aug; 24(4):728-30. PubMed ID: 21672182
[No Abstract] [Full Text] [Related]
27. Family members' perceptions of genetic testing for malignant melanoma--a prospective interview study.
Bergenmar M; Hansson J; Brandberg Y
Eur J Oncol Nurs; 2009 Apr; 13(2):74-80. PubMed ID: 19179113
[TBL] [Abstract][Full Text] [Related]
28. The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry.
Lang J; Hayward N; Goldgar D; Tsao H; Hogg D; Palmer J; Stark M; Tobias ES; MacKie R
Genes Chromosomes Cancer; 2007 Mar; 46(3):277-87. PubMed ID: 17171691
[TBL] [Abstract][Full Text] [Related]
29. A novel germline mutation, P48T, in the CDKN2A/p16 gene in a patient with pancreatic carcinoma.
Moore PS; Zamboni G; Falconi M; Bassi C; Scarpa A
Hum Mutat; 2000 Nov; 16(5):447-8. PubMed ID: 11058911
[No Abstract] [Full Text] [Related]
30. Novel CDKN2A mutations detected in western Swedish families with hereditary malignant melanoma.
Erlandson A; Appelqvist F; Wennberg AM; Holm J; Enerbäck C
J Invest Dermatol; 2007 Jun; 127(6):1465-7. PubMed ID: 17255954
[TBL] [Abstract][Full Text] [Related]
31. A novel methionine-53-valine mutation of p16 in a hereditary melanoma kindred.
Yang G; Niendorf KB; Tsao H
J Invest Dermatol; 2004 Sep; 123(3):574-5. PubMed ID: 15304098
[TBL] [Abstract][Full Text] [Related]
32. From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients.
de Snoo FA; Kroon MW; Bergman W; ter Huurne JA; Houwing-Duistermaat JJ; van Mourik L; Snels DG; Breuning MH; Willemze R; Frants RR; Gruis NA
J Am Acad Dermatol; 2007 May; 56(5):748-52. PubMed ID: 17276542
[TBL] [Abstract][Full Text] [Related]
33. The P48T germline mutation and polymorphism in the CDKN2A gene of patients with melanoma.
Huber J; Ramos ES
Braz J Med Biol Res; 2006 Feb; 39(2):237-41. PubMed ID: 16470311
[TBL] [Abstract][Full Text] [Related]
34. The CDKN2a common variants: 148 Ala/Thr and 500 C/G in 3' UTR, and their association with clinical course of melanoma.
Lamperska KM; Przybyła A; Kycler W; Mackiewicz A
Acta Biochim Pol; 2007; 54(1):119-24. PubMed ID: 17351674
[TBL] [Abstract][Full Text] [Related]
35. CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma.
Blokx WA; Lesterhuis WJ; Andriessen MP; Verdijk MA; Punt CJ; Ligtenberg MJ
Am J Surg Pathol; 2007 Apr; 31(4):637-41. PubMed ID: 17414113
[TBL] [Abstract][Full Text] [Related]
36. Absence of germline epimutation of the CDKN2A gene in familial melanoma.
van Doorn R; Zoutman WH; Gruis NA
J Invest Dermatol; 2009 Mar; 129(3):781-4. PubMed ID: 18818678
[No Abstract] [Full Text] [Related]
37. Comment on "Clinical genetic testing for familial melanoma in Italy: a cooperative study".
Amato A; Russo A; Adamo V; Cannavò SP
J Am Acad Dermatol; 2010 Dec; 63(6):1099. PubMed ID: 21093666
[No Abstract] [Full Text] [Related]
38. CDKN2A: the IVS2-105A/G intronic mutation found in an Italian patient affected by eight primary melanomas.
Majore S; Catricalà C; Binni F; De Simone P; Eibenschutz L; Grammatico P
J Invest Dermatol; 2004 Feb; 122(2):450-1. PubMed ID: 15009729
[No Abstract] [Full Text] [Related]
39. CDKN2 mutations in melanoma.
Dracopoli NC; Fountain JW
Cancer Surv; 1996; 26():115-32. PubMed ID: 8783570
[No Abstract] [Full Text] [Related]
40. High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families.
Hocevar M; Avbelj M; Perić B; Zgajnar J; Besić N; Battelino T
Croat Med J; 2006 Dec; 47(6):851-4. PubMed ID: 17167857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
